Has Mitsi Long received payments from drug or device companies?

Yes. Drug and device makers reported $5,487 in general payments to Mitsi Long across 254 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mitsi Long did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mitsi Long come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mitsi Long

Psychiatric/Mental Health · Shreveport, LANPI 1740801752

Payments from drug & device makers

$5,487in general payments, 2019–2025

Across 254 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teva Pharmaceuticals USA, Inc.$1K
Neurocrine Biosciences, Inc.$1K
AbbVie$617
Alkermes, Inc.$571
Johnson & Johnson$495
Otsuka America Pharmaceutical, Inc.$410
plus $765 from 6 others

What the payments were for

Food & beverage$5,18394%
Education$3036%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teva Pharmaceuticals USA, Inc.	55	$1,452
Neurocrine Biosciences, Inc.	45	$1,177
AbbVie	52	$617
Alkermes, Inc.	26	$571
Johnson & Johnson	15	$495
Otsuka America Pharmaceutical, Inc.	18	$410
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	10	$232
Indivior Inc.	13	$175
Sunovion Pharmaceuticals Inc.	13	$150
Vanda Pharmaceuticals Inc.	3	$149
E.r. Squibb & Sons, L.L.C.	2	$34
Lundbeck LLC	2	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,487 in reported general payments places this provider in the 85th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
IngrezzaValbenazine Tosylate	21	$176,821
Invega SustennaPaliperidone Palmitate	51	$152,686
AristadaAripiprazole Lauroxil	23	$74,051
UzedyRisperidone	17	$56,234
VraylarCariprazine Hcl	33	$49,260
Abilify MaintenaAripiprazole	13	$37,752
Divalproex Sodium ErDivalproex Sodium	41	$3,051
Atomoxetine Hcl	18	$1,776
Divalproex Sodium	61	$1,711
Fluphenazine Decanoate	14	$1,675
Quetiapine Fumarate	75	$1,600
Sertraline Hcl	120	$1,576
Mirtazapine	42	$1,383
Trazodone Hcl	90	$1,218
Haloperidol Decanoate	34	$1,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza	$1,177	$176,82121 claims
Johnson & JohnsonInvega Sustenna	$495	$152,68651 claims
Alkermes, Inc.Aristada	$571	$74,05123 claims
Teva Pharmaceuticals USA, Inc.Uzedy	$1,452	$56,23417 claims
AbbVieVraylar	$617	$49,26033 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena	$410	$37,75213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Shreveport

Kimberly ForcinelShreveport$92K
Zachary FussellShreveport$9K
Lisa BakerShreveport$9K
Jaschandria BellShreveport$8K
Shannon JacksonShreveport$8K
Amy LacoutureBaton Rouge$663K
Amanda EymardHouma$617K
Amber LittlefieldBroussard$225K
Timothy PellegrinHouma$210K
Melissa GuilbeauLafayette$122K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →